Centogene
Mary brings over 20 years of experience in private and publicly listed international pharmaceutical and life science companies, including as an executive at Avillion, Perrigo, and Elan Corporation, as well as a non-executive director at Venn Life Sciences. Throughout her career, she has held significant financial and other management roles and supported value creation across a wide range of areas, including supporting development, approval, and launch of blockbuster products for neurology and immunology indications. Ms. Sheahan currently serves as CFO of Avillion LLP, a private equity-backed life sciences company focused on the co-development and financing of pharmaceutical products. In this role, she is also responsible for supporting Avillion’s partnerships with multinational pharmaceutical companies. Mary is also a qualified chartered accountant and has worked as an auditor with KPMG.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Centogene
2 followers
Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450, 000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients' blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.